Guide · Updated 2026
Semaglutide vs. Tirzepatide
One activates a single hormone receptor. The other activates two. That single difference explains most of what you'll notice.
The molecular difference in plain English
Both drugs mimic gut hormones released after you eat. Semaglutide mimics GLP-1 alone. Tirzepatide mimics GLP-1 and GIP together. GIP appears to amplify GLP-1's appetite-suppressing signal and adds an insulin-sensitizing effect. In practice, tirzepatide-treated patients feel fuller longer, lose more weight, and see slightly larger A1c drops at matched doses.
Products built on each molecule
| Molecule | Brand | Approved use |
|---|---|---|
| Semaglutide | Ozempic | Type 2 diabetes; CV risk in T2D |
| Wegovy | Weight loss; CV risk in obesity | |
| Rybelsus (oral) | Type 2 diabetes | |
| Tirzepatide | Mounjaro | Type 2 diabetes |
| Zepbound | Weight loss; OSA in obesity |
Head-to-head efficacy
SURPASS-2 (diabetes): tirzepatide beat semaglutide on A1c and weight. SURMOUNT-5 (obesity): tirzepatide produced 20.2% weight loss vs. 13.7% for semaglutide over 72 weeks. Across trials, the pattern holds — tirzepatide is roughly 30–50% more effective on weight endpoints.
Side effects and tolerability
Both share the same GI side-effect profile — nausea, diarrhea, constipation, occasional vomiting, and fatigue during dose escalation. Rates in trials are within a few percentage points of each other. Tirzepatide's higher potency can mean more intense symptoms at the top doses, and clinicians often keep patients on 5 mg or 7.5 mg tirzepatide (rather than pushing to 15 mg) if the mid-tier dose is working.
Safety data maturity
Semaglutide has been FDA-approved since 2017 (Ozempic) — nearly a decade of post-market surveillance including CV outcomes, kidney outcomes, and pregnancy exposures. Tirzepatide has been available since 2022 with strong trial data but a shorter real-world track record.
Cost and access
List prices are similar. Compounded semaglutide is more widely available than compounded tirzepatide (Lilly aggressively enforces against tirzepatide compounding). LillyDirect Zepbound vials at $349–$499/month currently make brand-name tirzepatide the cheapest cash-pay path for weight loss.
Which is right for you?
- Maximum weight loss: Tirzepatide (Zepbound).
- Longest track record: Semaglutide.
- Injection-averse: Rybelsus is the only oral option.
- CV risk reduction on-label: Semaglutide (both Ozempic and Wegovy).
- Sleep apnea + obesity: Tirzepatide (Zepbound).
FAQ
Which is stronger?
Tirzepatide. It activates GLP-1 and GIP receptors and produces roughly 50% more weight loss than semaglutide at max dose.
Are the side effects different?
The types are similar — nausea, GI upset, fatigue. Tirzepatide can cause slightly more intense GI effects during dose escalation.
Is one safer long-term?
Semaglutide has more years of post-market data. Tirzepatide has strong trial safety data but a shorter real-world track record.
Can I switch between them?
Yes, under supervision. You'd restart at the lowest dose of the new drug and titrate up on the standard schedule.
Which is cheaper compounded?
Semaglutide — compounded tirzepatide is far harder to source legally since Lilly's enforcement crackdown in late 2024.
See which providers match your situation
Take a 90-second questionnaire and we'll rank your top 3 telehealth providers by medication, budget, and state availability.
Find My Top 3 MatchesEducational content, not medical advice. Talk to a licensed clinician before starting or changing any medication.